Why We May Never Know Whether the $56,000-a-Year Alzheimer’s Drug Actually Works
The Food and Drug Administration’s approval in June of a drug purporting to slow the progression of Alzheimer’s disease was...
Elisabeth Rosenthal, editor-in-chief, joined KHN in September 2016 after 22 years as a correspondent with The New York Times, where she covered a variety of beats from health care to environment and did a stint in the Beijing bureau. While in China, she covered SARS, bird flu, and the emergence of HIV/AIDS in rural areas. Her 2013-14 series, “Paying Till It Hurts,” won many prizes for both health reporting and its creative use of digital tools. Her book, “An American Sickness: How Healthcare Became Big Business and How You Can Take It Back”), was a New York Times bestseller and a Washington Post notable book of the year. She is a graduate of Stanford University and Harvard Medical School and briefly practiced medicine in a New York City emergency room before converting to journalism.
The Food and Drug Administration’s approval in June of a drug purporting to slow the progression of Alzheimer’s disease was...